SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the Company will present data from an ongoing Phase 1 study of RDEA119, its lead mitogen-activated ERK kinase (MEK) inhibitor in development for the treatment of cancer, at the second annual meeting on Molecular Markers in Cancer, hosted by the American Society of Clinical Oncology (ASCO), National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer (EORTC) at the Westin Diplomat Resort & Spa in Hollywood, FL.
